Provided by Tiger Trade Technology Pte. Ltd.

Longeveron Inc

0.5503
-0.0585-9.61%
Volume:688.29K
Turnover:392.89K
Market Cap:11.74M
PE:-0.27
High:0.6100
Open:0.6016
Low:0.5500
Close:0.6088
52wk High:2.24
52wk Low:0.5500
Shares:21.33M
Float Shares:16.75M
Volume Ratio:2.28
T/O Rate:4.11%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.0427
EPS(LYR):-2.6164
ROE:-119.92%
ROA:-60.95%
PB:1.18
PE(LYR):-0.21

Loading ...

Longeveron Chief Science Officer and Chief Medical Officer Selected as Speakers at the Global Cardiovascular Clinical Trialists (Cvct) Forum

THOMSON REUTERS
·
Dec 03

Longeveron Granted Canadian Patent for Stem Cell Therapy Targeting Aging-Related Frailty and Cardiomyopathy

Reuters
·
Dec 02

Longeveron Granted Canadian Patent for Method of Using Stem Cells to Treat Non-Ischemic Dilated Cardiomyopathy and Aging-Related Frailty in Patients With Inflammaging

THOMSON REUTERS
·
Dec 02

Longeveron Stem Cell Therapy Reduces Neuroinflammation in Mild Alzheimer’s Disease, Phase 2 Trial Shows

Reuters
·
Dec 02

Longeveron New Mri Biomarker Data Linking Neuroinflammation to Clinical Outcomes in Patients With Mild Alzheimer’s Disease Presented at the Clinical Trials on Alzheimer’s Disease Conference (Ctad 2025)

THOMSON REUTERS
·
Dec 02

Longeveron Highlights Laromestrocel Data Showing Reduced Brain Neuroinflammation in Mild Alzheimer’s Disease

Reuters
·
Nov 19

Longeveron Laromestrocel Data in Alzheimer’s Disease Selected for Poster Presentation at the Clinical Trials on Alzheimer’s Disease Conference (Ctad 2025)

THOMSON REUTERS
·
Nov 19

Longeveron granted U.S. patent for administration of MSCs

TIPRANKS
·
Nov 12

Longeveron Granted U.S. Patent for Stem Cell Therapy Targeting Aging-Related Frailty

Reuters
·
Nov 12

Longeveron Granted U.S. Patent for Method of Treating Aging-Related Frailty in Patients With Inflammaging Using Its Proprietary Stem Cell Therapy

THOMSON REUTERS
·
Nov 12

Longeveron Inc - Patent Rights in U.S. Through 2038

THOMSON REUTERS
·
Nov 12

Longeveron Directors Khoso Baluch and Neha Motwani Resign

Reuters
·
Nov 12

Longeveron: Promising Outlook with Clinical Progress and Strategic Adjustments

TIPRANKS
·
Nov 07

Roth MKM Reaffirms Their Buy Rating on Longeveron (LGVN)

TIPRANKS
·
Nov 05

Longeveron Inc - on Track for Elpis Ii Results in Q3 2026 - SEC Filing

THOMSON REUTERS
·
Nov 05

Cellular therapy developer Longeveron's Q3 net loss widens

Reuters
·
Nov 05

Longeveron Q3 EPS USD -0.39

Reuters
·
Nov 05

Longeveron Q3 Operating Expenses USD 7.435 Million

THOMSON REUTERS
·
Nov 05

Longeveron Q3 EPS $(0.39) Misses $(0.26) Estimate, Sales $137.000K Miss $284.667K Estimate

Benzinga
·
Nov 05

Longeveron® to Report Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025

GlobeNewswire
·
Oct 28